DJIA 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%

Lexicon Pharmaceuticals, Inc.

NASDAQ: LXRX

+ Add to Portfolio

company name or ticker

Lexicon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcri

Lexicon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)
5/16/2013 by Seeking Alpha

Lexicon Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript

5/10/2013 by Seeking Alpha

Lexicon Issues Update on Phase 2 Trial of LX4211 In Type 1 Diabetes

Lexicon Issues Update on Phase 2 Trial of LX4211 In Type 1 Diabetes
5/10/2013 by Benzinga

Market Wrap for Monday, April 29: Stocks Start Week With a Rally

4/29/2013 by Nasdaq

Market Wrap for Monday, April 29: Stocks Start Week With a Rally

4/29/2013 by Benzinga

Lexicon Pharma Falls on Concerns Raised by Merck-Pfizer Diabetes Partnership

4/29/2013 by TheStreet

Lexicon Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript

2/21/2013 by Seeking Alpha

Keryx Defies Gravity

Keryx defies gravity with its secondary offering.
1/30/2013 by DailyFinance

Lexicon Pharmaceuticals' Management Presents at 31st Annual J.P. Morgan Healthcare Conference (Trans

Lexicon Pharmaceuticals' Management Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)
1/9/2013 by Seeking Alpha

Why Lexicon Pharmaceuticals Is Poised to Underperform

Market-lagging returns could be written in this 2-Star.
1/3/2013 by DailyFinance
See More Articles...